Information Provided By: 
Fly News Breaks for June 24, 2016
CEMP
Jun 24, 2016 | 09:33 EDT
After attending the company's investor day, Needham analyst Alan Carr says that he expects Cempra to have moderate success in commercializing its Solithera independently, due to challenges for a biotech company in penetrating urgent and primary care. However, and despite believing that the commercial opportunity is probably larger in hands of Big Pharma, the analyst thinks the company's share price does not reflect what Cempra can accomplish independently. He reiterates a Buy rating and $48 price target on the shares.
News For CEMP From the Last 2 Days
There are no results for your query CEMP
